Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine.

Qdenga vaccine elicits serotype-skewed antibody responses with only 8% of DENV-naïve adults developing tetravalent neutralization, mainly targeting DENV-2.

• Why it matters: Understanding immune imprinting and vaccine design effects is crucial for improving dengue vaccine efficacy and achieving balanced immunity across serotypes.
• What they did: Longitudinal immunological profiling of 110 adults from a dengue-endemic region was conducted, measuring humoral and cellular responses, including serotype-specific neutralizing titers.
• The result: Findings show that immune imprinting and vaccine backbone constrain response breadth and magnitude, with poor DENV-4 neutralization, informing strategies for long-term protection and booster development.